EUVIMED · CrossrefZeitschrift
Journal of Experimental & Clinical Cancer Research
ISSN 1756-9966 · Springer Science and Business Media LLC
Neueste Artikel
Comprehensive characterization of bone marrow remodeling in lung cancer identifies tasquinimod as a potential adjuvant to anti-PD-L1 immunotherapy
Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for high-risk neuroblastoma
Intratumoral IL-12/Flt3L mRNA-LNP therapy engages cDC1, NK and T cell immunity in checkpoint-resistant melanoma
Nuclear PAPSS1 drives pancreatic cancer progression and immune evasion through the PTS–CBX3–EP300–H3K4ac axis
CLDN6 defines a liver-metastatic CMS4 subgroup in colorectal cancer via CLDN6–SRC–FOXO1 signaling and epigenetic reprogramming
Redirecting expanded effector lymphocytes with engineered HER2 antibodies extends therapeutic sensitivity in HER2-non-amplified and trastuzumab-refractory breast cancer
GLOBO H targeting CAR T Cells: generation and preclinical activity in gastrointestinal cancer cell lines
NAT10-mediated acetylation of JunB drives melanoma progression by enforcing SLC27A1-dependent lipid metabolic reprogramming
Correction: Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma
KLHL6 drives colorectal cancer liver metastasis through ubiquitin-mediated degradation of MBD2 that triggers CLDN4 activation
Correction: Targeting the CAF-GDF15 axis attenuates AKT-mediated mitochondrial rewiring and chemoradiation resistance in esophageal adenocarcinoma
Targeting the splicing factor RBM39 reduces mitotic fidelity and enhances taxane cytotoxicity in triple negative breast cancer cells
COMP-MUC1 interaction mediated by the Arg628-Asp543 salt bridge confers ferroptosis resistance to drive prostate cancer bone metastasis
Retraction Note: Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression
Correction: MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation
Advillin stabilizes YAP to sustain oncogenic transcription and creates therapeutic vulnerability in rhabdomyosarcoma
SPATS2 triggers immune evasion and anti-PD-1 resistance of hepatocellular carcinoma by inducing dendritic cell phagocytic dysfunction
Correction: Suppression of Spry1 reduces HIF1α‑dependent glycolysis and impairs angiogenesis in BRAF‑mutant cutaneous melanoma
Correction: MIF/CD74 axis is a target for novel therapies in colon carcinomatosis
ELF3 (E74 like ETS transcription factor 3) promotes tumor growth and autophagy in pancreatic cancer
Correction: JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal‑rich
Correction: Insulin-like growth factor binding protein 3 promotes radiosensitivity of oral squamous cell carcinoma cells via positive feedback on NF-κB/IL-6/ROS signaling
Development of a cell-penetrating peptide for intracellular delivery of a biologically active HPV E6 inhibitor in cervical cancer cells
The ABHD10-ACSL4 axis promotes pancreatic ductal adenocarcinoma growth via suppressing ferroptosis
Circulating blood microbiome biomarkers as liquid biopsy in breast cancer
Targeting the ANKRD54/ELOVL6 axis suppresses malignancy in BRAF mutant colorectal cancer by disrupting fatty acid metabolism and promoting ferroptosis
Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma
Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance
PROTAC technology for sensitizing melanoma to immune checkpoint therapy
Beyond conventional immune checkpoints: the LILRB axis as a dual regulator of tumor and immune cell states
EUVIMED